Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment

References

• Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207–3213
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib. interim results of a phase 2 study. Blood 2007;110:2309–2315
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–6661
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Muller MC, Radich JP, Khoury HJ, Khoroshko N, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib. 15-month median follow-up. Blood 2009;113:6322–6329
   PubMed Web of Science ®Google Scholar
• Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352–359
   PubMed Web of Science ®Google Scholar
• Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, Servadei F, Walters BC, Wilberger JE. Surgical management of acute subdural hematomas. Neurosurgery 2006;58:S16–S24 (discussion Si-iv)
   PubMed Web of Science ®Google Scholar
• Pitner SE, Johnson WW. Chronic subdural hematoma in childhood acute leukemia. Cancer 1973;32:185–190
   PubMed Web of Science ®Google Scholar
• Yhim HY, Kim HS, Lee NR, Song EK, Kwak JY, Yim CY. Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 2012;95:585–587
   PubMed Web of Science ®Google Scholar
• Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52:1211–1214
   PubMed Web of Science ®Google Scholar
• Song KW, Rifkind J, Al-Beirouti B, Yee K, McCrae J, Messner HA, Keating A, Lipton JH. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 2004;45:1633–1636
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee DH, Lee YR, Kim DK, Bae SH, Hwang JY, Kwon KA, Lee S, Han JY, Kim KU, et al. A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate. Korean J Hematol 2010;45:73–75
   PubMedGoogle Scholar
• Shimokaze T, Mitsui T, Takeda H, Kawakami T, Arai T, Ito M, Iwaba A, Izumino H, Takahashi N, Kanno M, et al. Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Hematol Oncol 2009;26:448–453
   PubMed Web of Science ®Google Scholar
• Erkut M, Erkut N, Ersoz S, Arslan M, Sonmez M. A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. Acta Haematol 2010;123:205–206
   PubMedGoogle Scholar
• Ishida Y, Terasako K, Oshima K, Sakamoto K, Ashizawa M, Sato M, Kikuchi M, Kimura S, Nakasone H, Okuda S, et al. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Int J Hematol 2010;92:542–546
   PubMed Web of Science ®Google Scholar
• Ono Y, Mori T, Kato J, Yamane A, Yajima T, Iwao Y, Hibi T, Okamoto S. Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia. Int J Hematol 2010;92:556–558
   PubMed Web of Science ®Google Scholar
• Chen J, Zheng Z, Shen J, Zhou Y. The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia. Leuk Lymphoma 2010;51:941–943
   PubMed Web of Science ®Google Scholar
• Sunami Y, Sato E, Ichikawa K, Yasuda H, Komatsu N. Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase. Rinsho Ketsueki 2011;52:282–286
   PubMedGoogle Scholar
• Patodi N, Sagar N, Rudzki Z, Langman G, Sharma N. Haemorrhagic colitis caused by dasatinib. Case Rep Hematol 2012;2012:417106
   PubMedGoogle Scholar
• Sartor C, Papayannidis C, Chiara Abbenante M, Iacobucci I, Broccoli A, Venturi C, Testoni N, Ferrari A, Martinelli G. Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome. Hematol Rep 2013;5:26–27
   PubMedGoogle Scholar
• Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, Monia Z, Sriha B, Abderrahim K. Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 2013;4:59–62
   PubMedGoogle Scholar
• Chisti MM, Khachani A, Brahmanday GR, Klamerus J. Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis. BMJ Case Rep 2013;2013 ; doi: 10.1136/bcr-2013-200610
   Google Scholar
• Saito M, Izumiyama K, Mori A, Irie T, Tanaka M, Morioka M, Saga A, Musashi M, Kato T, Meguro T, et al. Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Rinsho Ketsueki 2014;55:130–132
   PubMedGoogle Scholar
• Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011;117:5198–5206
   PubMed Web of Science ®Google Scholar
• Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242–245
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261–263
   PubMed Web of Science ®Google Scholar
• Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P, Recher C, Payrastre B. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114:1884–1892
   PubMed Web of Science ®Google Scholar
• Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med 1998;188:267–276
   PubMed Web of Science ®Google Scholar
• Quek LS, Pasquet JM, Hers I, Cornall R, Knight G, Barnes M, Hibbs ML, Dunn AR, Lowell CA, Watson SP. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood 2000;96:4246–4253
   PubMed Web of Science ®Google Scholar
• Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP. Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 2003;160:769–780
   PubMed Web of Science ®Google Scholar